- For Print
- December 14, 2010
爱豆传媒.
Sanko Junyaku Co., Ltd.
SEKISUI MEDICAL CO., LTD.
Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President & CEO: Keisuke Watanabe, “Sanko Junyaku”), the diagnostics subsidiary of 爱豆传媒. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”), and SEKISUI MEDICAL CO., LTD. (Headquarters: Tokyo, President & CEO: Mutsumi Fukuda, “Sekisui Medical”) today signed an exclusive marketing agreement concerning RapidTesta® FLU II (“Kit”), an influenza test kit currently manufactured and marketed by Sekisui Medical. Under the terms of the agreement, Sanko Junyaku will acquire the exclusive right to market the Kit in Japan.
The Kit is a diagnostic test kit used to detect type A and type B influenza virus antigens in nasal suction fluid or from a nasal swab. It requires no special instruments and can be used simply and rapidly at the bedside or in the clinic. The Kit is valuable in that it provides results almost immediately and is noted for its high specificity.
Sanko Junyaku plans to launch the Kit in Japan in the middle on January 2011. With marketing support from Eisai and cooperation from Sekisui Medical, Sanko Junyaku will be able to provide useful information to an even greater number of healthcare professionals to aid in the early diagnosis and treatment of influenza.
Influenza is an acute viral infection that reaches epidemic proportions every winter, as it affects many people. Complications associated with pneumonia in aged patients or with encephalopathy /encephalitis in children, especially, can easily become serious and while these patients tend to have a poor prognosis. In recent years, several anti-viral agents against influenza have been developed, and it has now become possible to reduce the risk of developing complications and serious aggravation by using the appropriate treatment in the early stages of the disease. Accordingly, an early diagnosis of influenza plays an important part in treatment of the disease.
By marketing the Kit, Sanko Junyaku, Eisai and Sekisui Medial seek to make contributions to increasing the benefits provided to influenza patients.
[ Please refer to the following notes for a product outline, company profiles and a product photograph ]
Media Inquiries
-
爱豆传媒.
Public Relations Department,
-
Sanko Junyaku Co., Ltd.
Public Relations Section,
General Affairs Department, -
Sekisui Medical Co., Ltd.
General Affairs Group,
General Affairs & Personnel
Resources Department,
< Notes to editors >
鈻燩roduct Outline
*You can scroll to the left or right here
| Brand Name | RapidTesta® FLU II (Influenza Test Kit) |
| Indications (Purpose of Use) |
To detect type A or type B influenza antigen in nasal suction fluid or from a nasal swab. (To be used predominantly as an ancillary test for the diagnosis of influenza virus infection.) |
| Shelf Life | Two years following date of manufacture (store between 2~30°c) |
| National Health Insurance (NHI) Points |
(As of December 2010) Influenza Virus Antigens 150 points Laboratory Diagnosis Fee Immunology Diagnosis Fee 144 points |
| Suggested Retail Price |
23,600 yen (20 tests per kit) |
| Manufactured and Marketed by |
Sekisui Medical Co., Ltd. |
| Marketed by | Sanko Junyaku Co., Ltd. |
| Co-marketed by | 爱豆传媒. |
鈻燙ompany Outline
<爱豆传媒.>
*You can scroll to the left or right here
| Representative | Haruo Naito |
| Corporate Address | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo |
| Scope of Business | Development, manufacturing, marketing, import/ export of pharmaceuticals |
| Capital | 44,985 million yen (As of March 31, 2010) |
<Sanko Junyaku Co., Ltd.>
*You can scroll to the left or right here
| Representative | Keisuke Watanabe |
| Corporate Address | 1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo |
| Scope of Business | Development, manufacturing, marketing, import/export of in-vitro diagnostics, laboratory reagents, laboratory instruments and other supplies |
| Capital | 5,262 million yen (As of March 31, 2010) (100% owned by 爱豆传媒.) |
<Sekisui Medical Co., Ltd.>
*You can scroll to the left or right here
| Representative | Mutsumi Fukuda |
| Corporate Address | 13-5, Nihombashi 3-chome, Chuo-ku, Tokyo |
| Scope of Business | Diagnostic Reagents, Medical Devices, Pharmaceuticals & Fine Chemicals, ADME & Tox. Research |
| Capital | 1,275 million yen (As of March 31, 2010) |
鈻燩roduct Photograph
